PubMed: Chemotyping of Δ8-THC-Containing e-Liquids Analyzed during the 2019-2020 New York State EVALI Investigation

PubMed: Chemotyping of Δ8-THC-Containing e-Liquids Analyzed during the 2019-2020 New York State EVALI Investigation

J Anal Toxicol. 2021 Oct 19:bkab107. doi: 10.1093/jat/bkab107. Online ahead of print.

ABSTRACT

The investigation of the 2019-2020 E-cigarette or Vaping Product Use-Associated Lung Injury (EVALI) outbreak in New York State provided a unique opportunity to examine the formulations and chemical components found in clandestine cannabis-containing e-liquids. In this EVALI investigation, it was determined that an unusually high proportion (16%) of the cannabis e-liquids analyzed contained significant levels of Δ8-tetrahydrocannabinol (Δ8-THC). Although not thought to be the causative agent in the outbreak, the manufacturing origin of vaping e-liquids containing large concentrations of Δ8-THC was of great interest, since high Δ8-THC concentrations are not observed in the extracts of common cannabis strains. A principal component analysis of multiple cannabinoid concentrations revealed clusters of similar or identical Δ8-THC-containing products. This technique may be useful in identifying common manufacturing sources in this and future investigations. Several possible manufacturing methods to enrich Δ8-THC appear in literature and are discussed based on their likelihood as sources of this cannabinoid in these samples from the EVALI investigation. The presence of high levels of Δ8-THC in numerous illicit vaping products may implicate cannabidiol, which is readily available at low cost, as its synthetic precursor.

PMID:34665862 | DOI:10.1093/jat/bkab107

#CBD #Hemp https://pubmed.ncbi.nlm.nih.gov/34665862/?utm_source=Chrome&utm_medium=rss&utm_campaign=None&utm_content=1jYCQzi_o_qLYr-oQfnMhShgOXkvGma3vcnBGJtrBhuJMOvEVJ&fc=None&ff=20211020065859&v=2.15.0 October 19, 2021 10:00 am